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Abstract
ABAT deficiency (OMIM 613163) is a rare inborn error of metabolism caused by recessive variants in the gene
4-aminobutyric acid transaminase (ABAT), which is responsible for both the catalysis of GABA and maintenance
of nucleoside pools in the mitochondria. To date, only a few patients have been reported worldwide. Their
clinical presentation has been remarkably consistent with primary features of severe psychomotor retardation,
encephalopathy, hypotonia, and infantile-onset refractory epilepsy. We report a new case of ABAT deficiency
that marks an important departure from previous clinical findings. The patient presented at age 6 months with
global developmental delay, hypotonia, hypersomnolence and mild choreiform movements. At age 18 months,
the subject’s clinical presentation was still milder than all previously reported patients and, most notably, did
not include seizures. Clinical whole exome sequencing revealed two heterozygous ABAT missense variants that
are rare and predicted damaging, but never before reported in a patient and were reported as variants of
unknown significance. To test the potential pathogenicity of the variants identified in this patient we developed a
cell-based system to test both functions of the ABAT protein via GABA transaminase enzyme activity and mtDNA copy
number assays. This systematic approach was validated using vigabatrin, the irreversible inhibitor of ABAT, and
leveraged to test the functionality of all ABAT variants in previously reported patients plus the variants in this new case.
This work confirmed the novel variants compromised ABAT function to similar levels as variants in previously
characterized cases with more severe clinical presentation, thereby confirming the molecular diagnosis of this patient.
Additionally, functional studies conducted in cells from both mild and severe patient fibroblasts showed similar levels
of compromise in mitochondrial membrane potential, respiratory capacity, ATP production and mtDNA depletion.
These results illustrate how cell-based functional studies can aid in the diagnosis of a rare, neurological disorder.
Importantly, this patient marks an expansion in the clinical phenotype for ABAT deficiency to a milder presentation that
is more commonly seen in pediatric genetics and neurology clinics.
Introduction
ABAT deficiency (OMIM 613163), also called GABA-
Transaminase deficiency, is a rare inborn error of
metabolism caused by recessive variants in the gene 4-
aminobutyric acid transaminase (ABAT). To date, only
a few patients have been reported worldwide [1–3].
Their clinical presentation has been remarkably consistent
with primary features of severe psychomotor retardation,
hypotonia, encephalopathy, and infantile-onset refractory
epilepsy.
ABAT encodes for GABA transaminase, the enzyme
responsible for catabolizing the principal inhibitory
neurotransmitter gamma-aminobutyric acid (GABA).
Recent work demonstrated that ABAT has a second role
in the mitochondrial nucleoside salvage pathway convert-
ing dNDPs to dNTPs [1]. This function of the protein is
essential for maintenance of nucleoside pools available to
the mitochondrial genome replication machinery. Thus
inhibition of this protein results in both elevated levels of
GABA and reduced copy number of mitochondrial gen-
ome in patient tissues [1].
Current diagnostic paradigms for genetic disorders in-
clude exome sequencing. However, typically 25% of cases
receive a molecular diagnosis [4, 5]. The standards and
guidelines outlined by American College of Medical
Genetics and Genomics and the Association of Molecular
Pathology for interpretation of sequence variants point to
functional validation of missense variants as essential for
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proof of pathogenicity of a variant of unknown signifi-
cance [6]. These should be ‘well-established in vitro or in
vivo functional studies supportive of a damaging effect on
the gene or gene product’. For most genes known to cause
single gene Mendelian disorders such assays have not
been established in the clinical diagnostic setting despite
the rising need driven by increased use of exome sequen-
cing in this setting.
We describe a new case of ABAT deficiency with a
milder clinical presentation than previous patients. We
review previous cases and discuss the common clinical
hallmarks clinical of this disorder. Additionally, we de-
vised a non-invasive strategy for functionally vetting var-
iants in the ABAT gene for potential pathogenicity,
demonstrated its efficacy, and leveraged this platform for
providing functional validation of pathogenicity of variants
and substantiate the molecular diagnosis for this unusual
patient. Importantly, this patient marks an expansion in
the clinical phenotype for ABAT deficiency to a milder
presentation that is more commonly seen in pediatric gen-
etics and neurology clinics and our results illustrate a




All subjects and their families were consented to an Insti-
tutional Review Board -approved protocol for participation
in research study. Genomic DNA was extracted from
blood and fibroblasts according to standard protocols.
Genetic testing including exome sequencing was conducted
at Baylor Genetics Laboratories, Houston, Texas. All vari-
ants identified were annotated using HG19, NM_000663.4,
and NP_000654.2.
Cell culture
Glioblastoma cells T98G were obtained from the American
Type Culture Collection (Manassas, VA). The cells were
grown in complete Eagle’s Minimum Essential Medium
(MEM) supplemented with 10% FBS. Separately, T98G cells
were cultered with MEM and various doses of vigabatrin
(Sigma-Aldrich, St. Louis, MO). The growth medium with
vigabatrin was replaced every day for 10 days. After 10 days,
the cells were harvested to assess mtDNA content and
GABA-T enzymatic activity. Fibroblasts were grown in
MEM supplemented with 15% FBS, 1x MEM-vitamins,
2 mM L-Glutamine, 1 mM sodium pyruvate, 1x penicillin/
streptomycin, 1x non-essential amino acids, and 0.41 μM
uridine. Separately, in order to synchronize cells in G0, cells
were grown in in “low-serum” media 1% FBS for 10 days.
Cells were maintained as a monolayer in a humidified 37C,
5% CO2 atmosphere.
Quantitation of mtDNA copy number
mtDNA content of the control and patients cells were
analyzed using real-time qPCR method as previously
described [1]. The ND1 region of human mtDNA was
amplified using forward primer 5′ GTCAACCTCGCT
TCCCCACCCT 3′ and reverse primer 5′ TCCTGCG
AATAGGCTTCCGGCT′, giving a fragment of 108 bp;
A fragment of human beta 2 microglobulin gene was
amplified using forward primer 5′ CGACGGGAGGGT
CGGGACAA 3′ and reverse primer 5′ GCCCCGCGA
AAGAGCGGAAG 3′ giving a fragment of 118 bp. The
real time PCR reaction was performed in triplicate for
each DNA sample using a StepOne Plus RT-PCR system
(Applied Biosystems). PerfeCTa SYBR Green FastMix
ROX was purchased from Quanta Biosciences. 500nM of
each primer, and 10 ng of total genomic DNA extract
were used per reaction. After real-time PCR amplifica-
tion, the mtDNA content (mtDNA/B2M ratio) was cal-
culated using the formula: mtDNA content =1/2ΔCt,
where ΔCt = CtmtDNA − CtB2M.
GABA-T enzymatic activity assay
GABA-T enzymatic activity was determined using a
GABA-T assay kit (Biomedical Research Service Center,
Buffalo University, NY) according to manufacturer in-
structions. Briefly, the assay is based on sequential GABA
transamination reaction and glutamate dehydrogenase re-
action, which couples the reduction of iodonitrotetrazo-
lium to iodonitrotetrazolium-formazan (ε = 18 mM-1cm-1
at 492 nm). Reactions were terminated by adding 3%
acetic acid (Sigma-Aldrich, St. Louis, MO) and optical
density (OD) at 492 nm was measured using a plate reader
(Phoenix Sunrise, Tecan). Readings were averaged and
control wells readings were subtracted from sample wells
readings (ΔOD). GABA-T activity was calculated using
the following formula: GABAT activity (μmol/(L.min) =
(ΔOD x 1000 x 155 μl)/(60 min x 0.6 cm x Ɛ x 10 μl) =
ΔOD x 23.92, where 155 μl is the total reaction volume,
0.6 cm the light path in the 96 well plate, 10 μl the volume
of sample in each well.
shRNA knock down of ABAT
Oligonucleotides containing shRNA hairpins that target
the 3’UTR of ABAT were custom designed and cloned
into the pGIPZ vector (GE Healthcare). Control fibro-
blasts were infected with two independent shRNA hair-
pins plus a scrambled shRNA and 72 hours post infection
QRT-PCR and Western Blot for ABAT were performed
on these cells as described.
Quantitation of ABAT mRNA by qRT-PCR
RNA was extracted and cDNA synthesized using stand-
ard protocols. Quantitative real-time PCR experiments
were performed using a StepOne Plus RT-PCR system
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(Applied Biosystems), RT2 qPCR Primer Assays for
Human GAPDH and ABAT (SABiosciences) and Per-
feCTa SYBR Green FastMix ROX (Quanta Biosciences).
All assays were conducted in triplicate and the results are
shown as the average and standard deviation.
Cloning and functionally testing ABAT variants
To assess the effect of ABAT mutations on mtDNA con-
tent and GABA-T enzymatic activity, we expressed
ABAT patient variants in glioblastoma T98G cells using
a lentiviral delivery system as previously described [1].
Wild-type ABAT entry ORF clone (NM_000663.3; clone
ID: IOH13638) was utilized to generate ABAT ORFs
containing patient variants by site-directed mutagenesis
as described [1]. The following mutant PCR primers
were used:
(c.631C > T):ctgccccgactacagcatcTtctccttcatgggcgcgttcc
atgggagga; (c.275G > A):gttgatgtggacggcaaccAaatgctggatc
tttattcccagatctcctc); (c.1433 T > C):attcgtttccgtcccacgcCg
gtcttcagggatcaccacgctcacctgtt; (c.659G > A):atgggcgcgttcc
atgggaAgaccatgggttgcttagcgaccacgcactc; (c.454C >T): cctt
gctctcggtggctTccaaagggatgtc; (c.1393G >C): aaggtgtggtgttg
Cgtggctgtggtgac
Mutation p.Q66del was generated by PCR using
ABAT-specific primers fused to attB1/B2 recombination
sequences (Invitrogen) designed following manufacture’s
recommendations.
shRNA hairpins that target the ABAT 3′UTR and a
scrambled shRNA were transferred from the pGIPZ
vector into the pGIPZ-GW by enzymatic digestion
(XhoI +MluI) and ligation. Then the cDNAs correspond-
ing to mCherry, ABAT wild-type, or ABAT mutants were
transferred from Donor223 vector (Invitrogen) into the
pGIPZ-GW by LR recombination reaction (Invitrogen).
Virus production was conducted as previously de-
scribed [7]. Infectious lentiviral supernatant was used to
infect healthy growing fibroblasts with polybrene (Sigma)
before selection by puromycin. After puromycin selection,
the cells were maintained in culture for 10 days and then
harvested. mtDNA content and GABA-T activity were de-
termined as described.
Mitochondrial membrane potential
Mitochondrial membrane potential was assessed using
MitoProbe DilC1(5) Assay kit for Flow Cytometry (Life
Technologies) as described [7]. Briefly, confluent cells
were harvested, washed in pre-warmed 37 °C 1X PBS and
counted using Vi-CELL cell viability analyzer (Beckman
Coulter). The cells were either stained directly with the
DilC1(5) dye at a final concentration of 50 nM for
30 minutes at 37 °C, 5% CO2 or pre-incubated with
50 mM of carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) for 15 minutes at 37 °C, 5% CO2 prior to stain-
ing with DilC1(5). After staining, the cells were washed
and visualized by flow cytometry, and the data analyzed
with FlowJo software. Triplicate results are reported and are
shown as the average and standard deviation.
Respiration studies using micro-scale oxygraphy
XF24 extracellular flux analyzer from Seahorse Biosci-
ences was used to measure oxygen consumption rates
following standard protocols. Cells were plated the pre-
vious day of experiment at a density of 30,000 cells per
well. XF assay medium (5 mM glucose/galactose, 2 mM
Pyruvate) in XF base media (Seahorse Biosciences) was
prepared and pH adjusted to 7.0. Oxygen consumption
rates were measured for 3 min with 3 min of mixing and
2 min of waiting period in between addition of each cel-
lular stress reagents: 500nM Oligomycin, 500nM FCCP,
100nM Antimycin and 100nM Rotenone (Sigma-Aldrich).
Cells were counted post-analysis using ViCell cell viability
analyzer (Beckman Coulter) and counts were used to




Subject 1 was a male of European ancestry who came to
clinical attention at 6 months of age with the non-spe-
cific findings of global hypotonia, developmental delay
and mild choreiform movements. In addition, the child
displayed hypersomnolence to the extent of sleeping 20 –
22 hours per day. No consanguinity or family history of
neurological disorder was reported.
Cranial MRI conducted on Subject 1 at 9 months of
age showed extensive T2 hyperintensity in the deep
white matter that is evidence of diffuse, mild deep white
matter hypomyelination. The pattern of myelination ob-
served is consistent with the expected pattern of myelin
maturation at 4 months of life, indicating a lag of
5 months behind the subject’s chronological age. There
were no structural brain abnormalities.
An EEG conducted at age 13 months showed back-
ground activity was diffusely slow with a slow occipital
rhythm, indicating the presence of a diffuse disturbance
in cerebral function. There were no focal or lateralizing
features and no epileptiform activity was recorded. A sub-
sequent EEG at 16 months continued to display diffuse
slowing of background activity with no seizures recorded
even though multiple choreiform movements and staring
spells occurred during recording. However, this study did
observe the presence of spike and wave complexes in the
right central, left parietal, and midline centroparietal
regions that increased in frequency during sleep. These
findings indicated the presence of focal, potentially epi-
leptogenic processes in these regions.
At the age of 18 months the patient had severe
hypotonia, developmental delay without regression and
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oculomotor apraxia. The subject displayed some fine cho-
reiform movements but to that point no clinical seizures.
He had reached some developmental milestones: he had
some head control when sitting, tracked faces and smiled
appropriately, ate and drank by mouth including solid
food.
Genetic and biochemical investigations reveal ABAT
deficiency
Diagnostic whole exome sequencing reported two variants
of unknown significance in ABAT. The subject appeared
compound heterozygous for two missense variants: ABAT
NM_000663.4 c.454C > T;p.Pro152Ser and c.1393G >C;
p.Gly465Arg. Sanger sequencing confirmed segregation in
the family consistent with an autosomal recessive disorder,
with c.454C > T present in the mother and c.1393G >C in
the father. Both variants scored maximally damaging by
SIFT, PolyPhen-2, LRT, MutationTaster. Indicators of evo-
lutionary constraint were high for both variants with Gerp
and PhyloP 5.6 and 2.7 for p.Pro152Ser and 5.1 and 2.4
p.Gly465Arg. The composite metric CAAD Phred also
scored high with of 30 and 26. Neither variant was
observed in ExAC, Exome Sequencing Project or 1000
genomes project. Neither variant has been previously
reported in an ABAT deficiency patient and since both
were missense variants, by the guidelines of American
College of Medical Genetics these are considered vari-
ants of uncertain significance (VUS) and in the diag-
nostic exome report were classified as VUS.
Cerebral spinal fluid (CSF) displayed GABA free level
of 247 nmol/L (17-67) and total level of 33.4 umol/L
(4.2-13.4). CSF was tested for neurotransmitters prior to
exome sequencing and was normal, but GABA was not
included in this panel of neurotransmitters. Subject 1 ex-
hibited normal plasma and CSF amino acids.
Phenotype expansion in the clinical presentation of ABAT
deficiency
The clinical presentation of Subject 1 overlaps with pre-
viously reported cases of ABAT deficiency while extend-
ing the phenotype to a milder presentation (Table 1). All
cases reported show profound global hypotonia and hy-
persomnolence. All cases were demonstrated to have
elevated GABA in CSF or brain. However, significant
distinctions can be made between this newest case of
ABAT deficiency with regard to developmental mile-
stones, seizure activity and cranial MRI abnormalities.
The clinical presentation of all previously reported
cases of ABAT deficiency is summarized in Table 1 [1–3].
In addition, Subject 4, a sibling of Subjects 2 and 3, is
newly reported here and can be briefly described as having
a highly similar clinical presentation to her siblings origin-
ally described in Besse et al, 2015. All cases except Subject
1 showed profound developmental delay with no patients
reported to reach any significant developmental mile-
stones. In contrast, Subject 1 achieved some milestones,
albeit delayed, including rolling (9 months), sitting with
assistance (12 months) and eating solid food (18 months).
Seizure activity reported in previous patients was
neonatal- or infantile-onset. Subjects 2,3,4 displayed
hypsarrhythmia starting at ages 3-6 months that did not
respond to treatment [1]. Subjects 5,6 exhibited convul-
sions in the first day of life [3]. Subject 7 first experienced
seizures at 8 months [2]. All of these patients’ seizures per-
sisted throughout life and none were controlled by medi-
cations. In contrast, at 18 months Subject 1 had not yet
displayed overt seizures.
Subject 1 showed clear delays in myelination like other
reported subjects with ABAT deficiency, however, the
imaging phenotype of Subject 1 is notably milder than
other patients. Illustrated in Fig. 1, the cranial MRI for
Subjects 2 and 3 demonstrated that while Subjects 2 and
3 were older at time of imaging (13 and 17 months re-
spectively), myelination in the posterior limbs of the
internal capsules (PLICs) is even less complete than
Subject 1 at age 9 months, and is associated with re-
stricted diffusion on ADC, suggestive of more severe
hypomyelination. Also, in contrast to Subject 1, these
two subjects exhibited diffuse yet mild cerebral atrophy.
In the 13 month old, bilateral hypomyelination was also
visualized in the brainstem middle cerebral peduncle, cen-
tral tegmental areas, and medial thalami (not pictured).
The 17 month old also exhibited asymmetry with dispro-
portionate right-sided atrophy. Similarly, imaging in Sub-
ject 7 showed marked hypomyelination, with diffusion
weighted images revealing high signal intensity in the in-
ternal and external capsules and much of the subcortical
white matter, with restricted diffusion abnormality [2].
These imaging observations between subjects correlated
with their clinical severity.
Non-invasive functional testing for ABAT deficiency
ABAT functions in the mitochondrial inner membrane
to catabolize GABA and to produce nucleoside pools
essential for the maintenance of the mitochondrial gen-
ome. We tested both functions of the protein in a human
cellular model. Vigabatrin is an irreversible inhibitor of
ABAT, typically prescribed for its anticonvulsant effects
resulting from its ability to elevate GABAergic tone. In
initial experiments, control cells were cultured in the pres-
ence of vigabatrin at varying doses ranging from 0 – 300
uM. mtDNA content decreased as dose increased and was
diminished to 50% of control at the 200 uM dose which
we have previously observed [1] (Fig. 2a). The same cells
under same conditions were analyzed for GABA-T activity
to test this function of ABAT. Like mtDNA content,
GABA-T activity diminished with increasing dose of
Vigabatrin and uniformly showed greater compromise
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Table 1 Clinical Features of subjects with ABAT Deficiency
Family 1 Family 2 Family 3 Family 4
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7









Gender M F M F F M F
Age at last follow-up 2 yr 7 yr 5 yr 1 yr 2 12 months 7 yr
Current age 2 yr deceased 7 yr deceased deceased deceased -
Age of clinical presentation 6 mo 3 mo 2 mo 2 mo birth birth 7 mo
Age at death - 7 yr - 1 yr 2 yr 12 mo -
Ophthalmologic Cortical visual impairment No Yes Yes Yes NA NA NA
Optic nerve atrophy No Yes Yes Yes NA NA NA
Developmental
Milestones
Global developmental delays Yes Severe Severe Severe Severe Severe Severe
Hold up head 2 years No No No No No No
Roll over 9 mo No No No No No No
Sit up 12 mo (c assistance) No No No No No No
Ambulation No No No No No No No
Expressive language coos/babbles No No No No No No
Neurologic Hypotonia Yes Yes Yes Yes Yes Yes Yes
Abnormal movements Yes No No No No No No
Hypersomnia Yes Yes Yes Yes Yes Yes Yes
Seizures, age of onset No 3 mo 4 mo 4 mo birth birth 7 mo
Seizures, controlled by
medication





Normal at 3 mo,
Hypsarrhythmia
at 6 mo









Cranial MRI Atrophy No Yes Yes Yes - - Yes
Decreased white matter No Yes Yes Yes - - Yes
Hypomyelination Yes Yes Yes Yes - - Yes






Elevated in CSF - Elevated by brain MRS
Family 1 this manuscript
Family 2 Besse et al 2015 [1]
Family 3 Jaeken et al 1984 [3]











compared to control than mtDNA content at every
dose. GABA-T activity was 50% of control activity at
the 100 uM dose and 25% of control at 200 uM in this
cellular model.
We next utilized this cellular model to test the func-
tional consequences of ABAT variants identified in all re-
ported patients for both functions of ABAT. In this allelic
series experiment we utilized genetic knockdown and
expression of wildtype ABAT as controls. The shRNA-
induced knock-down of ABAT expression reduced
ABAT protein levels to 19% of control (Fig. 2b) and
these cells displayed GABA-T activity at 14% of control
and mtDNA copy number at 33% of control (Fig. 2c).
Non-transfected controls cells and those transfected
with non-targeting hairpin, eGFP, or wildtype ABAT in
cells all resulted in GABA-T activity and mtDNA
content at highly similar ‘normal’ levels (Fig. 2c). Every
patient allele tested universally resulted in compro-
mised function in both GABA-T activity and mtDNA
content. mtDNA content in cells expressing individual
patient alleles ranged from 36 – 75% of control. Simi-
larly, GABA-T activity was decreased and ranged from
15 – 63% of control.
The allele present in Family 2, c.631C > T, reduced
GABA-T activity to 31% and mtDNA to 51%. Given that
the affected individuals from this family are homozygous
for this allele this may represent a reasonable proxy for
activity in patient tissue. Subjects with ABAT deficiency
in Family 3 were compound heterozygous for ABAT
c.199-231del and c.275G > A and each of these alleles
individually compromised activity to 15% (GABA-T) /
36% (mtDNA) and 63% (GABA-T) / 73% (mtDNA)
Fig. 1 Cranial MRI shows a consistent pattern of hypomyelination across ABAT patients. MRI of Subject 1 (S1) at age 9 months shows extensive
T2 hyperintensity in the deep white matter that lags ~5 months behind the patient’s chronological age, suggesting diffuse mild hypomyelination.
However, the anterior limb of the internal capsule is hyperintense on T1, and partially hypointense on T2, with a non-restricted ADC map. In
contrast, while Subjects 2 (S2) and 3 (S3) are older at 13 and 17 months, myelination in the posterior limbs of the internal capsules is less
complete and associated with restricted diffusion on ADC, suggestive of more severe hypomyelination. Additionally, Subjects 2 and 3 exhibit
diffuse yet mild cerebral atrophy. Subject 3 also exhibits asymmetry with disproportionate right sided atrophy. C: caudate, P: putamen, GP: globus
palidus, T: thalamus, PLIC: posterior limb of the internal capsule
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Fig. 2 GABA-T enzymatic activity and mtDNA copy number are diminished in cells expressing ABAT deficiency patient variants. a. Cells cultured
in the presence of vigabatrin, the irreversible inhibitor of ABAT, show deficits in GABA-T activity and mtDNA copy number that follow a dose-response.
b. Immunostaining for ABAT protein levels in cells transformed with non-targeting shRNA (shNT) and shRNA targeting ABAT (shABAT) show ABAT
protein levels 19% of control in cells transformed with shABAT. c. GABA-T enzymatic activity and mtDNA copy number was measrured in cells
transformed with shNT, shABAT, eGFP, open reading frame for wild-type ABAT (ABAT WT), and the mutations identified in ABAT deficiency patients.
All experiments conducted in T98G cells
Fig. 3 Mitochondrial bioenergetics are compromised in ABAT deficiency patients. a. Mitochondrial membrane potential is reduced in fibroblasts
from ABAT deficiency patients Subject 1 (S1), Subject2 (S2), and Subject3 (S3). b. Microscale oxygraphy demonstrated that ATP production, c.
Basal respiration, d. Maximum respiration, and e. Reserve capacity were all relatively similarly compromised in ABAT deficiency patients, both mild
(S1) and severe (S2, S3)
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respectively. Given the null allele present in this family
we presume the ABAT homodimer containing both of
these alleles would function more closely to the activity
of the null allele than the missense allele.
In an effort to phenocopy compound heterozygous pa-
tient tissue as closely as possible in this cellular system
we created double mutant knock-in alleles. Affected in-
dividuals in Family 4 are compound heterozygous for
c.1433 T > C and c.659G > A. Individually these alleles
diminished activity to 27% (GABA-T) / 47% (mtDNA)
and 20% (GABA-T) / 43% (mtDNA) respectively, and
the double mutant bearing both alleles showed further
compromise with 16% (GABA-T) / 39% (mtDNA) which
is essentially the same level of activity as the shRNA
knock-down and null allele (c.199-231del). Subject 1 is
compound heterozygous for c.454C > T and c.1393G >C.
These two alleles individually and combined demonstrate
less compromise in activity compared to others. Allele
c.454C > T shows 61% (GABA-T) / 75% (mtDNA) which
is comparable to the performance of the Subject 3’s milder
allele which is present in this patient in combination with
a null allele. The second allele in Subject 1 is also a milder
allele showing 46% (GABA-T) / 65% (mtDNA) activity.
The double mutant shows 39% (GABA-T) / 60%
(mtDNA), which is comparable to deficiency in activity
observed in the cells cultured with 150 uM Vigabatrin.
Cellular investigations demonstrate similarly
compromised mitochondrial bioenergetics in mild and
severe ABAT deficiency cases
We examined the inner mitochondrial membrane poten-
tial in a fibroblast cell line established from Subject 1 and
compared this to membrane potential in fibroblasts from
two previously reported affected siblings with ABAT defi-
ciency, Subjects 2 and 3. The electron transfer activity of
the respiratory chain complexes pumps protons from the
mitochondrial matrix into the intermembrane space, cre-
ating an electrical potential across the inner mitochondrial
membrane. This membrane potential was significantly
compromised in all three subjects compared to controls
(Fig. 3a). Subject 1 is the mildest and least compromised,
however there is more differential between the two af-
fected siblings, Subjects 2&3, than between Subject 1 and
Subjects 2&3 who carry the same mutation and we cannot
conclude that Subject 1 fibroblast has a milder phenotype,
and rather must attribute these differences to variation
amongst immortalized cell lines.
Oxygraphic measurements of respiration in live cells
demonstrated reduced capacity in basal and maximum
respiration as well as reserve capacity (Fig. 3b-e). ATP
production was also compromised to approximately
50%. All three patient cell lines showed similar levels of
compromise.
Decreased mtDNA copy number in patient cells
ABAT deficiency has been demonstrated to result in de-
creased mtDNA content in patient cells [1]. In normal
media where cells are cycling, the reduction in mtDNA
copy number is approximately 70 - 80% in all three pa-
tient cell lines (Fig. 4). Low serum media pauses cell
cycle in G0 which forces mitochondria to rely on the
mitochondrial nucleoside salvage pathway to supply
nucleosides to the mtDNA replication machinery, which
continues even in G0 while the nuclear genome replica-
tion machinery is halted. ABAT was shown to be essential
for converting dNDPs to dNTPs in the mitochondrial nu-
cleoside salvage pathway and as a result when ABAT defi-
ciency patient cells are cultured in low serum media they
show greater reduction in mtDNA content. Subject 1
shows a lesser decrease in mtDNA content when in low
serum media compared to Subjects 2 and 3. Subject 1
shows 65% of control while Subjects 2 and 3 display 55%,
a statistically significant difference p = 0.0004 (Fig. 4).
Discussion
We describe a subject who represents a phenotypic ex-
pansion for ABAT deficiency. We devised and validated
a non-invasive strategy for functionally vetting variants
in ABAT and successfully provided functional validation
of pathogenicity of this subject’s VUS. Further, we com-
pared the cellular function of this patient’s fibroblasts to
previous more severely affected cases and show similar
levels of dysfunction in mitochondrial membrane poten-
tial, respiratory capacity, ATP production, and copy
number of the mtDNA genome.
Fig. 4 mtDNA copy number is decreased in ABAT deficiency
patients. Healthy control (C) and patient fibroblasts (S1, S2, S3) were
either grown in media with FBS 15% (NM) or in “low-serum” media
FBS 1% for 10 days (LSM) mtDNA copy number was measured. NS =
non-statistically significant, *** p-value < 0.0001
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Review of published cases of ABAT deficiency con-
verges upon signature clinical features across cases. All
cases reported showed severe encephalopathy, profound
global hypotonia, elevated GABA in CSF or brain, cra-
nial MRI findings of hypomyelination with restricted
diffusion abnormality in PLICs. Equally important to
note are the differences between clinical presentations.
In particular, this patient demonstrates that a lack of
overt seizures and, notably, the ability to obtain some
developmental milestones, albeit delayed. Additionally,
cranial MRI for subjects with more severe clinical
presentation demonstrated varying degrees of atrophy
in addition to more severe delays in myelination with
corresponding areas of restricted diffusion in the
PLICs.
The cellular system innovated and leveraged to test
the functional consequences of ABAT variants identified
in all reported patients for both functions of ABAT is a
model that can be extrapolated for other genes. The
ABAT deficiency patient allelic series showed that all
known patient mutations inhibit GABA-T activity to less
than 30% of normal activity, except for three. One of
these mutations was found as a compound heterozygous
with a null mutation and the patient had a severe
phenotype. Two other mutations that had less severe ef-
fects in vitro were observed in the milder patient, Sub-
ject 1, lending some support for the ability of this in
vitro assay to distinguish severity of mutation and sup-
port for the notion that this milder patient’s phenotype
may be milder due to having two less debilitating
mutations.
Notably, both vigabatrin and patient mutations appear
to compromise GABA-T activity more so than mtDNA
copy number. The 200 uM dose of vigabatrin reduced
GABA-T to 25% of normal and mtDNA to 50% of nor-
mal. This dose of vigabatrin is comparable to what is
prescribed to control seizures and impairs GABA-T ac-
tivity and mtDNA copy number to similar levels as the
more severe patient mutations; and yet have very different
outcomes in ABAT deficiency patients versus patients
who receive viagabatrin therapy. These data suggest that
the debilitating effects of ABAT deficiency are a result
of disturbance to ABAT function during embryonic
development.
This patient illustrates how a personalized medi-
cine approach consisting of functional vetting of an
individual patient’s mutations can aid in the diagno-
sis of genetic disorders. This includes neurological
disorders and others that commonly require exten-
sive and invasive testing. Importantly, this patient
marks an expansion in the clinical phenotype for
ABAT deficiency to a milder presentation that is
more commonly seen in pediatric genetics and neurology
clinics.
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